Euroopan unioni - suomi - EMA (European Medicines Agency)

rad neurim pharmaceuticals eec sarl - melatoniini - unihäiriöiden ja ylläpidon häiriöt - psyykenlääkkeiden - melatonin neurim is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.

Euroopan unioni - suomi - EMA (European Medicines Agency)

amryt pharmaceuticals dac - octreotide acetate - akromegalia - aivolisäkkeen ja hypotalamuksen hormonit ja analogit - mycapssa is indicated for maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues.

Euroopan unioni - suomi - EMA (European Medicines Agency)

sfl pharmaceuticals deutschland gmbh - nyxthracis - anthrax - immunoseerumit ja immunoglobuliinit, - obiltoxaximab sfl is indicated in combination with appropriate antibacterial drugs in all age groups for treatment of inhalational anthrax due to bacillus anthracis (see section 5. obiltoxaximab sfl is indicated in all age groups for post-exposure prophylaxis of inhalational anthrax when alternative therapies are not appropriate or are not available (see section 5.

Euroopan unioni - suomi - EMA (European Medicines Agency)

rhythm pharmaceuticals netherlands b.v. - setmelanotide - liikalihavuus - antiobesity preparations, excl. ruokavalion tuotteita - imcivree is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed bardet biedl syndrome (bbs), loss-of-function biallelic pro-opiomelanocortin (pomc), including pcsk1, deficiency or biallelic leptin receptor (lepr) deficiency in adults and children 6 years of age and above.

Euroopan unioni - suomi - EMA (European Medicines Agency)

deciphera pharmaceuticals (netherlands) b.v. - ripretinib - ruoansulatuskanavan stromal-kasvaimet - antineoplastiset aineet - qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (gist) who have received prior treatment with three or more kinase inhibitors, including imatinib.

Euroopan unioni - suomi - EMA (European Medicines Agency)

idorsia pharmaceuticals deutschland gmbh - daridorexant hydrochloride - unihäiriöiden ja ylläpidon häiriöt - psyykenlääkkeiden - quviviq is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.

Euroopan unioni - suomi - EMA (European Medicines Agency)

marinus pharmaceuticals emerald limited - ganaxolone - epileptic syndromes; spasms, infantile - muut epilepsialääkkeet - ztalmy is indicated for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (cdkl5) deficiency disorder (cdd) in patients 2 to 17 years of age. ztalmy may be continued in patients 18 years of age and older.

Suomi - suomi - Fimea (Suomen lääkevirasto)

merz pharmaceuticals gmbh - clostridium botulinum type a neurotoxin (150kd) - injektiokuiva-aine, liuosta varten - 50 yksikköä - botuliinitoksiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

merz pharmaceuticals gmbh - clostridium botulinum type a neurotoxin (150kd) - injektiokuiva-aine, liuosta varten - 100 yksikköä - botuliinitoksiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

esteve pharmaceuticals gmbh - triamcinolone hexacetonide - injektioneste, suspensio - 20 mg/ml - triamsinoloni